18-Hydroxycorticosterone
18-hydroxycorticosterone is an intermediate in the synthetic pathway of aldosterone and is formed from corticosterone by the action of CYP11B2 in the Zona glomerulosa of the adrenal gland. CYP11B2 activity is predominantly controlled by angiotensin II which regulates the synthesis and secretion of aldosterone. Primary hyperaldosteronism (PH; Conn Syndrome) is characterized by triad of hypertension, hypokalemia and inappropriate renal potassium wasting.
Increased plasma aldosterone with suppressed renin are characteristic of PH, however, once the diagnosis is established, it is necessary to distinguish the underlying pathophysiology. The differential diagnosis includes: a unilateral aldosterone producing adrenal adenoma (APA), bilateral idiopathic hyperaldosteronism (IHA), unilateral adrenal hyperplasia, Familial hyperaldosteronism (FH) Type I due to mutations in CYP11B1/CYP11B2, FH Type II due to mutations in CLCN2, FH Type III due to mutations in KCNJ5, FH Type IV due to mutations in CACNA1H, primary aldosteronism with seizures and neurologic abnormalities (PASNA) due to mutations in CACNA1D, pure aldosterone producing adrenal carcinoma, and ectopic aldosterone secreting tumors. The underlying pathology dictates the appropriate therapeutic intervention.
Increased in:
- Aldosterone-producing adrenal adenoma
- Adrenal hyperplasia
- Some adrenal carcinomas
- Familial hyperaldosteronism Types I-IV
| Population | Age / Timing | Reference Range |
| Premature | (26 to 28 weeks): day 4 | 10−670 ng/dL |
| (31 to 35 weeks): day 4 | 57−410 ng/dL | |
| Full-term | Day 3 | 31-546 ng/dL |
| 31 days to 11 months | 5−220 ng/dL | |
| 12 to 23 months | 18−155 ng/dL | |
| 24 months to 9 years | 6−85 ng/dL | |
| 10 to 14 years | 10−72 ng/dL | |
| Adults | 9−58 ng/dL | |
| 8:00 AM Supine | 4-21 ng/dL | |
| 8 AM supine upright | 5−46 ng/dL |
Serum (SST).
Stability
- Ambient : 24 hours
- Refrigerated : 24 hours
- Frozen : 90 days
- J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1188:123030. [PMID: 34871919]
- J Clin Endocrinol Metab. 2012;97(3):881-9. [PMID: 22238407]
- J Clin Endocrinol Metab. 2007;92(7):2648-51. [PMID: 17473070]
- Surg Pathol Clin. 2019;12(4):967-995. [PMID: 31672302]
- Int J Urol. 1996;3(6):491-3. [PMID: 9170579]
- Ann Clin Biochem. 1989;26 ( Pt 3):227-32. [PMID: 2669615]